Nephrology

A panel of glomerular disease specialists provide an overview of immunoglobulin A nephropathy (IgAN).

Hyporesponse to erythropoiesis-stimulating agents was associated with increased rates of red blood cell transfusions and poorer outcomes in patients with chronic kidney disease, highlighting the need for alternative anemia treatments.

Acute inpatient admission was higher in patients with persistent hyporesponse, compared to patients with acute hyporesponse or without hyporesponse.

A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants.

At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.

Results from the NOSTONE trial suggest the incidence of recurrence did not differ among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or once-daily placebo.

The company announced more feedback from the FDA after receiving a Complete Response Letter last March.

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease.

There was no significant differences in creatinine or estimated glomerular filtration rate between the readmission group and the no readmission group.

Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals.

The topline phase 2b data shows both 75 mg and 150 mg doses of atacicept resulted in a 31% mean reduction in proteinuria.

From a topical gene therapy to a debated heart failure option, a litany of unique agents are anticipated for FDA decision in the new year.

With the population aging, there is a need for new treatments in nephrology.

Therapeutic candidate Sparsentan could expand treatment options for 2 rare kidney diseases. Dr. Jula Inrig expands on the potential for the FSGs patient population.

The results show serum IgA-IgG immune complex levels decreased in both patients treated with atacicept 25 mg ab atacicept 75 mg over time.

Ardelyx was issued a Complete Response Letter in July requestion an additional trial.

Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

Low sodium intake is considered less than 2.3 grams per day.

Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.

In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.